Bemcentinib
- Generic Name
- Bemcentinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N8
- CAS Number
- 1037624-75-1
- Unique Ingredient Identifier
- 0ICW2LX8AS
- Background
Bemcentinib has been investigated for the treatment of Non-Small Cell Lung Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 44
- Registration Number
- NCT06516887
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 6
- Registration Number
- NCT06469138
- Locations
- 🇬🇧
Labcorp Clinical Research Unit Ltd., Leeds, United Kingdom
A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 64
- Registration Number
- NCT05469178
- Locations
- 🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland, United States
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 115
- Registration Number
- NCT04890509
- Locations
- 🇮🇳
Unity Trauma Center and ICU, Unity Hospital, Surat, Gujarat, India
🇿🇦Lakeview Hospital, Mowbray, Benoni, South Africa
🇮🇳Kasturba Medical College, Mangalore, Karnataka, India
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 45
- Registration Number
- NCT03824080
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
🇩🇪Universitätsklinikum Dresden, Dresden, Germany
🇫🇷CHU Hôtel Dieu Service d'Hématologie Clinique, Nantes, Nantes Cedex 1, France
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT03649321
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 122
- Registration Number
- NCT02488408
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Germany
🇮🇹Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
🇩🇪Medizinische Hochschule Hannover,Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation,, Hannover, Carl-Neuberg-Str, Germany
A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- BerGenBio ASA
- Target Recruit Count
- 40
- Registration Number
- NCT02424617
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Moffit Cancer Centre, Tampa, Florida, United States
🇺🇸Mary Crowley Cancer Research Unit, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.